29.01.2010 • News

Ashland Looks Positively at 2010

Ashland CEO Jim O'Brien told shareholders at its annual meeting that its improved financial results are better than normal seasonality would indicate and that it had exceeded its cost-cutting goals through December. Cost savings on a continuing annual basis hit $405 million by year end, better than its $400 million target, he said.

The company earned $86 million, or $1.10 per share, in the first quarter of its 2010 fiscal year. That compared with a loss of $119 million, or $1.73 per share, in the same period a year earlier.

"If there is a negative on the horizon, it would be raw materials costs," O'Brien said.

Ashland's goal, he said, is to be in a global No. 1 or strong No. 2 position in each of the markets in which it operates.

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read